Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 224 от 240

Активно (без набиране) Фаза 2

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Localized Prostate Carcinoma Prostate Adenocarcinoma Stage I Prostate Cancer AJCC v8 Stage II Prostate Cancer AJCC v8

Apalutamide is an anti-androgen that blocks the effect of testosterone on prostate cancer growth. This phase IIa trial is designed to determine whether very low doses of apalutamide, given for 3 to 4 weeks before prostate surgery to men with prostate cancer confined to the prostate gland, reduces plasma levels of PSA (a biomarker of apalutamide's ability to block testosterone). If low dose apalutamide lowers PSA levels in this setting, further study of this agent in men with localized prostate cancer who wish to delay definitive therapy with surgery or radiation may be warranted.

Начало: 23.07.2021 Край: 31.01.2027 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT04530552

Активно (без набиране) Фаза 1

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Neuroendocrine Neoplasm

This phase Ib trial is to find out the best dose, possible benefits and/or side effects of peposertib when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell formation, so as to help block the formation of growths that may become cancer. Radioactive drugs, such as lutetium Lu 177 dotatate, may deliver radiation directly to tumor cells and not harm normal cells. Adding peposertib to lutetium Lu 177 dotatate may kill more tumor cells.

Начало: 22.07.2021 Край: 30.06.2026 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT04750954

Активно (без набиране)

Dietary Oils to Sustain Energy Study

Overweight and Obesity

The research study is an intervention and feasibility crossover design pilot study designed to assess if consuming 3 study foods made with either soybean oil or palm oil per day for 4 weeks can alter whole blood, plasma and erythrocyte fatty acids and body weight in overweight/obese adults. Additionally, the study will assess the adherence to consuming 3 study foods per day for 4 weeks and to assess if participant remain unaware of (or masked to) which study food group (soybean oil vs palm oil) they are consuming.

Начало: 19.07.2021 Край: 30.12.2026 Възраст: 25–80 г.

United States Ohio State University NCT04975763

Активно (без набиране) Ранна Фаза 1

Hematoma Block Versus Bier Block for Closed Fracture Reduction

Distal Radius Fractures

The investigators objective of this study is to evaluate the effectiveness of hematoma block versus intravenous regional anesthesia (Bier block) during closed reduction of distal radius fractures.

Начало: 15.07.2021 Край: 01.07.2027 Възраст: 18–80 г.

United States University of Utah NCT05086224

Активно (без набиране) Фаза 3

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Psoriatic Arthritis

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

Начало: 13.07.2021 Край: 10.06.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +18 Bristol-Myers Squibb NCT04908202

Активно (без набиране) Фаза 1/2

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Hemophagocytic Lymphohistiocytosis

This study is a multi-site Phase Ib/II, 2-arm non-randomized clinical trial to determine the efficacy and tolerability of a response-adapted regimen combining ruxolitinib, dexamethasone, and etoposide as Frontline therapy for patients with newly diagnosed hemophagocytic lymphohistiocytosis (HLH) or as Salvage therapy for patients with relapsed/refractory HLH. Primary Objective * To determine the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for patients with newly diagnosed HLH. Secondary Objectives * To describe the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for patients with relapsed/refractory HLH. * To describe the overall response and outcome for patients with newly diagnosed or relapsed/refractory HLH who are treated with this response-adapted ruxolitinib-containing regimen. Exploratory Objectives * To estimate the pharmacokinetic (PK) parameters of ruxolitinib, assess covariates of ruxolitinib pharmacokinetics, and test whether the drug's effectiveness is correlated with systemic drug exposure. * To query specific immunologic biomarkers and determine whether the levels of these biomarkers correlate with disease response and outcome.

Начало: 13.07.2021 Край: 01.08.2026 Възраст: 6–22 г.

United States St. Jude Children's Research Hospital NCT04551131

Активно (без набиране) Фаза 4

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Lennox Gastaut Syndrome Dravet Syndrome Tuberous Sclerosis Complex

This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.

Начало: 07.07.2021 Край: 31.03.2028 Възраст: от 1 г.

United States Jazz Pharmaceuticals NCT05044819

Активно (без набиране)

Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

Advanced Parkinson Disease

This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia). Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing. In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.

Начало: 06.07.2021 Край: 01.09.2026 Възраст: от 18 г.

Austria, Belgium, Bulgaria +11 Britannia Pharmaceuticals Ltd. NCT05043103

Активно (без набиране) Фаза 1

Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

Mature B-cell Malignancies

The purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy for the selected B-cell malignancy dose finding cohorts, and evaluate the safety and tolerability of the ramp-up dosing schedule in the evaluated disease types.

Начало: 05.07.2021 Край: 01.06.2026 Възраст: от 18 г.

China BeiGene NCT04883957

Активно (без набиране)

Live Stream of Prehospital Emergency Ultrasound in Patients With Acute Dyspnoea

Echocardiography Acute Dyspnea

Background: Acute dyspnoea is a common symptom in prehospital emergency medicine. As ultrasound gained in importance for diagnosis in patients with acute respiratory distress, it plays even a role in the prehospital setting. However, prehospital emergency ultrasound (PEU) remains challenging and requires knowledge and skills. New prehospital ultrasound devices offer the possibility for tele-supervision. The impact of tele-supervision of PEU in patients with acute dyspnoea is unclear. Objective: This prospective observational study aims to evaluate the effect of PEU with tele-supervision on diagnosis, treatment strategies and cognitive load in comparison to PEU without tele-supervision in patients with acute dyspnoea. Methods: In total 350 prehospital emergency patients with acute dyspnoea will be included in this study. Patients will be observed in two groups. In group 1 PEU will be performed with tele-supervision, whereas in group 2 PEU will be performed without tele-supervision (tele-supervision not available).

Начало: 01.07.2021 Край: 31.12.2026 Възраст: от 18 г.

Austria Medical University of Vienna NCT04817488

Активно (без набиране) Фаза 2

Phase ll Study of HEC585 in Patients With IPF

Idiopathic Pulmonary Fibrosis

A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis

Начало: 30.06.2021 Край: 11.12.2026 Възраст: 40–80 г.

China Sunshine Lake Pharma Co., Ltd. NCT05060822

Активно (без набиране) Фаза 3

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

Начало: 30.06.2021 Край: 01.09.2028 Възраст: 18–130 г. Лечение

Australia, Austria, Belgium +20 AstraZeneca NCT04964934

Активно (без набиране) Фаза 1/2

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer

Gastric Cancer

This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.

Начало: 28.06.2021 Край: 31.03.2027 Възраст: от 18 г.

China, South Korea, United States Idience Co., Ltd. NCT04725994

Активно (без набиране)

Secondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol

Hookah Smoking Secondhand Aerosol Vascular Stiffness Vaping

In the United States, secondhand smoke is the third leading preventable cause of death. Flavored hookah (waterpipe) tobacco smoking, a highly social activity common in hookah bars, is a key source of SHS exposure. While smoke-free air laws have decreased exposure to secondhand smoke, the majority of laws do not include hookah smoking. Thus, as a social outlet for youth and young adults, hookah smoke exposure may harm non-smokers, including women of reproductive age or pregnant, hookah bar workers, children, and individuals with heart and lung disease. While more is known on the acute effects of active hookah smoking and the literature is emerging on active e-hookah vaping, little is known about the acute vascular effects of secondhand exposure to hookah smoke and aerosol. The study aims to examine the acute effects of secondhand exposure of hookah smoke and aerosol on endothelial and vascular function. Eligible volunteers will be invited to participate in a total of 3 study visits (2-3 hours each): e-hookah aerosol exposure, charcoal-heated hookah smoke exposure and smoke-free room air. Non-invasive blood pressure and blood flow measurements will be taken before and after the exposure sessions.

Начало: 25.06.2021 Край: 15.04.2027 Възраст: 21–49 г.

United States University of California, Los Angeles NCT04661683

Активно (без набиране) Фаза 3

Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment

Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm

This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems. Sleep problems such as insomnia, are common for cancer patients. Insomnia can be described as difficulty falling asleep, waking up many times during the night or waking up earlier than patient would like. Insomnia can increase fatigue and worsen quality of life. This trial may help researchers determine which treatment works better in reducing insomnia, BBT-CI or HEAL.

Начало: 24.06.2021 Край: 12.04.2027 Възраст: от 18 г.

United States University of Rochester NCORP Research Base NCT04829539

Активно (без набиране)

Implementing PrEP for Women Who Inject Drugs

HIV Intravenous Substance Abuse Women's Health Organization and Administration +2

Women who inject drugs are among the most vulnerable to acquiring HIV, but very few women who inject drugs are prescribed pre-exposure prophylaxis (PrEP) for HIV prevention largely due to barriers within our healthcare system. This research will consider the perspectives of women who inject drugs, healthcare providers, and clinic leadership to improve the way primary care and reproductive health clinics deliver PrEP to women who inject drugs, thereby reducing new HIV infections in this population.

Начало: 22.06.2021 Край: 24.03.2027 Възраст: от 18 г.

United States University of Pennsylvania NCT05360849

Активно (без набиране) Фаза 3

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy

Начало: 08.06.2021 Край: 06.11.2026 Възраст: 18–70 г.

Argentina, Bulgaria, Chile +12 AstraZeneca NCT04877691

Активно (без набиране)

Prosthesis Versus Active Exercise Program in Patients With Glenohumeral Osteoarthritis

Glenohumeral Osteoarthritis

Anatomical total shoulder arthroplasty (TSA) is a well-established treatment for pronounced glenohumeral osteoarthritis. However, the effectiveness of TSA has not been compared to non-surgical treatment in a randomised controlled trial. Shoulder exercises may be an effective treatment for reducing pain and improving function in glenohumeral osteoarthritis. The primary aim of this trial is to examine if TSA followed by standard postsurgical rehabilitation is superior to a 12-week exercise programme in patients with primary glenohumeral OA eligible for unilateral TSA. We hypothesise that surgical intervention followed by standard rehabilitation, results in clinically relevant (18-point, on a scale from 0-100) improvement compared to the exercise intervention.

Начало: 02.06.2021 Край: 25.05.2026 Възраст: 55–85 г.

Denmark, Finland, Norway University of Aarhus NCT04845074

Активно (без набиране) Фаза 2/3

Electro-Magnetic Convulsive Therapies for Depression: a Non-inferiority Study

Major Depressive Disorder Bipolar Depression

This study aims to compare the efficacy and safety profile of Magnetic Seizure Therapy and Electroconvulsive therapy.

Начало: 31.05.2021 Край: 30.06.2026 Възраст: 18–65 г.

Brazil University of Sao Paulo NCT05054699

Активно (без набиране) Фаза 3

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Начало: 27.05.2021 Край: 28.07.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Bulgaria +16 UCB Biopharma SRL NCT04901195

1 … 222 223 224 225 226 … 240